Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/32497093http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/32497093http://www.w3.org/2000/01/rdf-schema#comment"

Background

Hepatocellular carcinoma (HCC) is one of the most lethal and malignant tumours worldwide. New therapeutic targets for HCC are urgently needed. CYCLOPS (copy number alterations yielding cancer liabilities owing to partial loss) genes have been noted to be associated with cancer-targeted therapies. Therefore, we intended to explore the effects of the CYCLOPS gene RBM17 on HCC oncogenesis to determine if it could be further used for targeted therapy.

Methods

We collected data on 12 types of cancer from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) queries for comparison with adjacent non-tumour tissues. RBM17 expression levels, clinicopathological factors and survival times were analysed. RNAseq data were downloaded from the Encyclopaedia of DNA Elements database for molecular mechanism exploration. Two representative HCC cell models were built to observe the proliferation capacity of HCC cells when RBM17 expression was inhibited by shRBM17. Cell cycle progression and apoptosis were also examined to investigate the pathogenesis of RBM17.

Results

Based on 6,136 clinical samples, RBM17 was markedly overexpressed in most cancers, especially HCC. Moreover, data from 442 patients revealed that high RBM17 expression levels were related to a worse prognosis. Overexpression of RBM17 was related to the iCluster1 molecular subgroup, TNM stage, and histologic grade. Pathway analysis of RNAseq data suggested that RBM17 was involved in mitosis. Further investigation revealed that the proliferation rates of HepG2 (P = 0.003) and SMMC-7721 (P = 0.030) cells were significantly reduced when RBM17 was knocked down. In addition, RBM17 knockdown also arrested the progression of the cell cycle, causing cells to halt at the G2/M phase. Increased apoptosis rates were also found in vitro.

Conclusion

These results suggest that RBM17 is a potential therapeutic target for HCC treatment."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.org/dc/terms/identifier"doi:10.1371/journal.pone.0234062"xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Chen J."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Feng X."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Li C."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Peng J."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Dong S."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Tang X."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Zhou J."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Zhong Y."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Zhang L."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Deng L."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Su N."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/author"Ge S."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/date"2020"xsd:gYear
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/name"PLoS One"xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/pages"e0234062"xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/title"Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma."xsd:string
http://purl.uniprot.org/citations/32497093http://purl.uniprot.org/core/volume"15"xsd:string
http://purl.uniprot.org/citations/32497093http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/32497093
http://purl.uniprot.org/citations/32497093http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/32497093
http://purl.uniprot.org/uniprot/#_Q5W009-mappedCitation-32497093http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/32497093
http://purl.uniprot.org/uniprot/#_L8EAL0-mappedCitation-32497093http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/32497093
http://purl.uniprot.org/uniprot/#_Q96I25-mappedCitation-32497093http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/32497093
▶